Milestone Pharmaceuticals (MIST) Other Non-Current Liabilities (2020 - 2026)

Milestone Pharmaceuticals (MIST) has reported Other Non-Current Liabilities for 7 consecutive years, with $55.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 4.85% year-over-year to $55.6 million; the trailing twelve-month figure through Jun 2026 stood at $55.6 million (up 4.85% YoY), and the FY2025 full-year result was $55.6 million, up 4.85% from the prior year.
• Other Non-Current Liabilities held at $55.6 million in Q2 2026 per MIST's latest filing, from $55.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $55.6 million in Q3 2025 and bottomed at $34.4 million in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $51.6 million across 5 years, with a median of $53.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 35.11% in 2022, then soared 41.07% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $34.4 million in 2022, then jumped by 41.07% to $48.5 million in 2023, then rose by 9.53% to $53.1 million in 2024, then rose by 4.85% to $55.6 million in 2025, then changed by 0.0% to $55.6 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $55.6 million, $55.6 million, and $55.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.